Our Transactions

We combine deep, personal industry knowledge and M&A experience in biotechnology to support our clients in developing and executing their M&A strategy.

Ba 5

Our track record

Since 2019, we have completed 60 biotechnology strategy reviews, undertaken 20+ sell-side transactions & 30+ buy-side projects.

We support a broad set of transactions, including:

  • Mergers
  • Acquisitions
  • Management-led buyouts
  • Disposals (assets and stock)
  • Specialist Commercial Due Diligence (CDD)
  • We have a proprietary database of sellers globally, covering manufacturers, distributors and hybrid resellers.
PIVOTAL_LINKS_213092

Recent Transactions

Scicons Nordicmubio

2021

Pivotal Scientific represented Nordic MUBio in their acquisition of Scicons 

Abab Lsbio

2020

Pivotal Scientific represented Absolute Antibody in their acquisition by LSBio

Dianove Calibre

2020

Pivotal Scientific represented Dianova GmbH in their acquisition to Calibre Scientific